Skip to main content

Market For Patient Blood Management Is Expected To Reach US$ 18.4 Billion By 2027

 the global patient blood management market is valued at US$ 12.7 billion and is projected to expand at a high-value CAGR of 7.7% through 2027, as per the latest study by Fact.MR.

The world has witnessed a prominent increase in the incidence of blood disorders and this has led to the high demand for plasma and blood transfusions across the world, which is expected to favor the patient blood management market growth potential in the future. However, the market is expected to be faced with challenges such as the illegal stocking of blood, corruption in blood banks, and high costs of automated patient blood management systems.

Download Sample Copy of This Report –

https://www.factmr.com/connectus/sample?flag=S&rep_id=7783?PS

Key Takeaways from Market Study

  • The global patient blood management market in 2022 is valued at US$ 12.7 billion.

Key Companies Profiled

  • Macopharma

Winning Strategy

Patient blood management providers are focusing on automation as demand for automated blood management is witnessing a huge rise and is projected to continue to do the same across the forecast period. Many companies are expected to focus on collaborations and partnerships to enhance their market presence and drive revenue generation capacity.

This patient blood management research survey by Fact.MR, a market research and competitive intelligence provider, discusses all the key strategies adopted by major and minor companies to enhance their sales and revenue potential. Haemonetics Corporation, Bio-Rad Laboratories Inc., Immucor Inc., B. Braun Melsungen AG, Fresenius Se & Co. KGaA, Macopharma, and Biomérieux SA are some of the prime companies profiled in this study.

Patient Blood Management Industry Research Segments

  • By Product :

Read More: https://www.factmr.com/report/patient-blood-management-market

Comments